Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | KDM4A | O75164 | 2/20 | 0.43 |
| ▸ | KDM4B | O94953 | 2/20 | 0.43 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | KDM5C | P41229 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1001453 | 0.93 | KDM4A (0.42) | LMNAKMT2AKDM4AKDM4BKDM5B | |
| SCHEMBL1001273 | 0.92 | KAT6A (0.42) | LMNAKMT2AKDM4AKDM4BKDM5B | |
| SCHEMBL1000488 | 0.89 | LMNA (0.43) | LMNAKMT2AKDM4AKDM4BKDM5B | |
| SCHEMBL1001483 | 0.73 | SLC40A1 (0.54) | LMNAKMT2AGAAMAPTTSHR | |
| SCHEMBL1000940 | 0.73 | RAB9A (0.48) | LMNAKMT2ATSHRHTTL3MBTL1 | |
| SCHEMBL1002215 | 0.72 | SMN1; SMN2 (0.54) | LMNAKMT2AMAPTTSHRHTT | |
| SCHEMBL994515 | 0.70 | KDM4E (0.54) | LMNAKDM4AMAPTTSHRALDH1A1 | |
| SCHEMBL999897 | 0.70 | TSHR (0.45) | LMNAKMT2AKDM4AKDM4BKDM5B | |
| SCHEMBL1001546 | 0.69 | TSHR (0.49) | LMNAGAATSHRHTTL3MBTL1 | |
| SCHEMBL1002283 | 0.69 | RAB9A (0.44) | LMNAKMT2AKDM4AKDM4BKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280001-B1 | LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | MSD KK (JP) | 2014-10-15 | — | — | EP | claimed |
| EP-2280001-B1 | LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | MSD KK (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-8420823-B2 | Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient | MSD K.K. (JP) | 2013-04-16 | — | — | US | disclosed |
| EP-2280001-A1 | LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | Banyu Pharmaceutical Co., Ltd. (JP) | 2011-02-02 | — | — | EP | disclosed |
| US-20110009622-A1 | LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | MSD K.K. (JP) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009622-A1 | LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | ELOVL1, ELOVL6, ELOVL3 | LMNA 1767/4885KMT2A 473/4885KDM4A 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.